#54

Top 30 Abstracts

CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed Non-Muscle Invasive Bladder Cancer

Trinity J. Bivalacqua, MD, PhD;[1*] Siamak Daneshmand, MD;[2] Eugene Cone, MD;[3] Christopher M. Pieczonka, MD;[4] Laurence H. Belkoff, DO [5]
Matthew Mossanen, MD, MPH;[6] Vikram M. Narayan, MD[7] and Gary D. Steinberg, MD [8]

[1] University of Pennsylvania, Philadelphia, Pennsylvania [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California [3] Urology of Indiana, Greenwood, Indiana
[4] Associated Medical Professionals, Syracuse, New York [5] MidLantic Urology, Bala Cynwyd, Pennsylvania [6] Brigham and Women's Hospital, Boston, Massachusetts
[7] Emory University School of Medicine, Atlanta, Georgia [8] Rush University Medical Center, Chicago, Illinois

BACKGROUND

- **Patients with HR NMIBC whose disease trajectory falls outside the strict FDA guidance of BCG-UR represent a significant unmet need, often lacking access to clinical trials or evidence-based treatment options**.
- **Cretostimogene is an oncolytic immunotherapy with dual mechanisms of action; it selectively replicates in and lyses cancer cells while simultaneously amplifying the immune response against bladder tumors.**
- **BOND-003 evaluating cretostimogene in HR BCG-UR NMIBC with CIS population showed a 75.5% CR at anytime and median DoR of 27.9 months, with 0% ≥ Grade 3 TRAEs- consistent with previous findings.[1-6]**
- **Granted US FDA Fast Track and Breakthrough Therapy Designations in HR BCG-UR NMIBC CIS +/- Ta/T1**

CORE-008 is a phase 2, multi-arm, multi-cohort, open-label trial to evaluate the safety and efficacy of cretostimogene across HR NMIBC:

- **Cohort A**: BCG-Naïve NMIBC
- **Cohort B**: BCG-Exposed NMIBC
- **Cohort CX**: Combination with intravesical gemcitabine in BCG-UR or BCG-Exposed NMIBC

Abbreviations: CR = complete response; GEM= gemcitabine; HG= high-grade; HR= high-risk; EFS = event-free survival NMIBC = non-muscle invasive bladder cancer; TRAE = treatment-related adverse event; UR = unresponsive

References: **1** Burke, *J Urol*; 2012, **2** Packiam, *Urol Oncol*; 2018, **3** Li, AUA Meeting; 2022, **4** Li, *Nat Med*; 2024, **5** Tyson, AUA Meeting, 2025 **6** Bivalacqua, NEAUA Meeting, 2025

Acknowledgements: Sarah Donatelli, PhD; Jee-Hyun Kim, PhD; Pat Keegan, MD, MPH; Rebecca Tregunna, MD, MBA; Shelja Patel, PharmD and Vijay Kasturi, MD

SUO CTC Society of Urologic Oncology Clinical Trials Consortium, Inc.

CORE-008 COHORT B

BCAN 20 Years of Impact

Trial in Progress
Open for Enrollment (US & Canada)
BCG-Exposed CIS or Papillary Only
SUO-CTC Collaboration



METHODS

- **HR eligibility per AUA/SUO NMIBC guideline criteria**
- **Primary endpoint for CIS is CR at any time and HG-EFS for papillary-only**
- **Response Assessments include cystoscopy, biopsy as indicated & cytology every 3 months for first 2 years and every 6 months starting Year 3**
- **Key trial features: Broad & inclusive population, mandatory biopsy at week 51, central pathology review**

BCG-Exposed NMIBC:	Additional Endpoints:
BCG-Resistant: Persistent or recurrent HG Ta or CIS at the first evaluation that follows at least 5 of 6 doses of induction BCG, **OR**	**Duration of Response**
Delayed Relapse after Adequate BCG: HG recurrence outside of the BCG-UR window (>6 mo for Ta/T1 and >12 mo for CIS) but within 24 mo after the last dose of adequate BCG, **OR**	**CR/HG-EFS at 12 mo**
Delayed Relapse After Inadequate BCG: HG recurrence within 24 mo after the final dose of inadequate BCG (3–6 doses)	**All-Cause EFS**
	Bladder Cancer Specific Survival
	Cystectomy-Free Survival
	Progression-Free Survival
	Safety
	Exploratory: Overall Survival, Patient-Reported Outcomes, Molecular response



Contact Information: Trinity J. Bivalacqua, MD, PhD; Trinity.Bivalacqua@Pennmedicine.upenn.edu